Hepatitis B combination restores antibody and T cell responses
Biopharmaceutical company VBI Vaccines has revealed interim data from its Phase II study evaluating the combination of VBI-2601, VBI’s HBV immunotherapeutic candidate, and BRII-835, an HBV-targeting siRNA candidate, in chronically infected hepatitis B (HBV) patients. The data demonstrate that the combination therapy was generally well-tolerated, restored strong… Read More